Jiangzhenzhou

Ph.D. Professor of Pharmacology; Director of the New Drug Screening and Pharmacodynamics Evaluation Center, Director of the Animal Experiment Center and Deputy Director of the Key Laboratory of Drug Quality Control and Pharmacovigilance; Scholar of the 14th batch of “Six Talents Peak” high-level talent selection; Young academic leader of the Blue and Green Project in Jiangsu. Committee member of the Toxicology and Safety Research Branch of the Chinese Society of Traditional Chinese Medicine and the Clinical Drug Safety Research Professional Committee of the World Federation of Chinese Medicine Societies.

The main research direction is the molecular mechanism and drug intervention of drug-induced liver injury and muscle atrophy related diseases; Hosted five general projects of the National Natural Science Foundation of China, two general projects of the Jiangsu Provincial Natural Science Foundation, one sub-project of the National Natural Science Foundation's Major International Cooperation Research Special Project, and six other provincial and ministerial level vertical projects. 108 SCI papers have been published as first or corresponding author. 

1) Oncofetal SNRPE promotes HCC tumorigenesis by regulating the FGFR4 expression through alternative splicing. British Journal of Cancer. 2024, May 25.

2) Triptolide leads to hepatic intolerance to exogenous lipopolysaccharide and natural-killer-cell mediated hepatocellular damage by inhibiting MHC class I molecules. Phytomedicine. 2023,109:154621.

3) A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation. British Journal of Pharmacology. 2022, 179(6):1237–1250.

4) Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production. Cell Death & Disease. 2022, 13(341):1-12.

5) SEW2871 attenuates ANIT-induced hepatotoxicity by protecting liver barrier function via sphingosine 1-phosphate receptor-1-mediated AMPK signaling pathway. Cell Biology and Toxicology. 2021, 37:595-609.

6）TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle. 2021, 12(1): 192-208.

1) The role and mechanism of NK cell function-related protein MHC-I and MULT-1 in triptolide-mediated hepatic excessive immune response. National Natural Science Foundation of China (8227420)

2) The effect and mechanism of S1P-S1PR1 mediating bile duct cytogenic cholestasis. Natural Science Foundation of Jiangsu Province (BK20221526)

3)The mechanism of liver injury induced by Tripterygium wilfordii multiglycoside based on liver hypersensitivity to inflammatory stimuli. National Natural Science Foundation of China (82074114)

2018, The second prize of education and scientific research achievement award

2015, The first prize of Shandong province science and technology progress award

2014, The second prize of the science and technology progress award, ministry of education

2006, The first prize of Jiangsu province science and technology progress award